Boston, MA (PRWEB) August 01, 2014
Cambridge Biomedical Inc announces contract with a major biopharmaceutical company for a GCLP Bioanalytical Assays and Sample Testing project extending into 2015.
Cambridge Biomedical’s experience in bioanalytical assay development, optimization, validation and diagnostic testing coupled with their wide range of technology platforms was instrumental for the successful completion of negotiations.
Dr. John Reddington, COO of Cambridge Biomedical, commented, “Our scientific expertise, combined with our Quality Assurance and Regulatory systems, enables us to provide critical solutions to meet the bioanalytical needs of our partners in the burgeoning healthcare community.”
Since 1997, Cambridge Biomedical has partnered with our clients by providing a diverse range of services from pre-clinical to post market. Including; assay development, optimization, validation and diagnostic testing. Conveniently located to support the Northeast pharmaceutical development market, yet with a national and global reach. Our personalized project management, approach along with a focus on delivering quality results and regulatory submission ready documentation and rapid turnaround times, ensure we meet our client’s product development timelines.